Evidence map›Paper›PMID 32071913›Full record

ArticleLiver cancer2020

Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.

Angel Alsina, Masatoshi Kudo, Arndt Vogel, Ann-Lii Cheng, Won Young Tak, Baek-Yeol Ryoo, Thomas R Jeffry Evans, Carlos López López, Bruno Daniele, Soamnauth Misir and 4 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05546619 (Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05546619 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection

TypeinterventionalSponsorSulai LiuRan2022 to 2025Enrolled30ConditionsHepatocellular CarcinomaArmsHIPEC+tislelizumab + targeted therapy
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 13 institutions in 9 countries.

Angel AlsinaaTransplant and Specialty Services, Tampa General Hospital, Tampa, Florida, USA.
Masatoshi KudobDepartment of Medicine, Kindai University, Osaka, Japan.
Arndt VogelcDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany.
Ann-Lii ChengdDepartment of Medical Oncology, National Taiwan University Hospital, and National Taiwan University Cancer Center, Taipei, Taiwan.
Won Young TakeDepartment of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Baek-Yeol RyoofDepartment of Oncology, Asan Medical Center, and University of Ulsan College of Medicine, Seoul, Republic of Korea.
Thomas R Jeffry EvansgInstitute of Cancer Sciences, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, United Kingdom.
Carlos López LópezhOncology Service, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.
Bruno DanieleiDepartment of Oncology, Azienda Ospedaliera G. Rummo, Benevento, Italy and Ospedale del Mare, Naples, Italy.
Soamnauth MisirjFormerly of Eisai Inc., Woodcliff Lake, New Jersey, USA.
Min RenkEisai Inc., Woodcliff Lake, New Jersey, USA.
Namiki IzumilDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan.
Shukui QinmPLA Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China.
Richard S FinnnGeffen School of Medicine, Department of Medicine, UCLA Medical Center, Santa Monica, California, USA.
Eisai (United States) · US81th Hospital of PLA · CNAzienda Ospedaliera G.Rummo · ITBeatson West of Scotland Cancer Centre · GBKindai University · JPKyungpook National University · KRMarqués de Valdecilla University Hospital · ESMedizinische Hochschule Hannover · DEMusashino Red Cross Hospital · JPNational Taiwan University Hospital · TWRonald Reagan UCLA Medical Center · USTampa General Hospital · USUlsan College · KR

Funding

Cancer Research UK 11650Cancer Research UK 26813
6 · The paper itself

Abstract

introductionUnderstanding the relationship between subsequent-line therapies and overall survival (OS) is important for maximizing OS for patients with hepatocellular carcinoma.

objectiveIn this post hoc analysis, we investigated OS in lenvatinib- and sorafenib-treated patients from the REFLECT study, who then received subsequent anticancer medication during the survival follow-up period.

methodsThe follow-up period commenced at the first off-treatment visit after stopping the study medication and continued until study termination, withdrawal of consent, or death. OS and objective response rate were calculated for patients who did or did not receive poststudy anticancer medication for both treatment arms, as well as for the overall cohort. We investigated the subset of patients who responded to first-line treatment and subsequently received anticancer medication.

resultsThe OS for patients initially randomized to first-line lenvatinib (versus first-line sorafenib) and who then received any subsequent anticancer medication was 20.8 vs. 17.0 months (hazard ratio [HR] 0.87; 95% CI 0.67-1.14). The OS for patients who initially received first-line lenvatinib (versus first-line sorafenib) and who did not receive any subsequent anticancer medication was 11.5 vs. 9.1 months (HR 0.90; 95% CI 0.75-1.09). Responders to first-line lenvatinib who received subsequent medication had a median OS of 25.7 months (95% CI 18.5-34.6); responders to first line-sorafenib who received subsequent medication had a median OS of 22.3 months (95% CI 14.6-not evaluable).

conclusionsIn this post hoc analysis of all patients in the REFLECT study who received subsequent anticancer medication, OS was increased compared with patients who did not receive any subsequent anticancer medication. In a subset analysis of responders who had received subsequent anticancer medication, use of first-line lenvatinib led to a slightly longer median OS; more research is needed on the benefits of using first-line lenvatinib compared with sorafenib.

Indexed as

LenvatinibOverall survivalResponse statusSecond-line treatmentSorafenib

Identifiers

PMID32071913
PMCPMC7024884
OpenAlexW2995953853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.